Updated:
HealthPointCapital
HealthPointCapital is a musculoskeletal-focused private equity firm founded by John McCormick, targeting orthopedics, spine, and dental technology buyouts.
HealthPointCapital
HealthPointCapital launched in 2002 when John C. McCormick, a former DLJ Merchant Banking managing director, saw an arbitrage in applying institutional buyout discipline to the fragmented musculoskeletal sector. The firm operates from New York, running a concentrated portfolio built entirely around orthopedic, spine, and dental technology — an intentional bet that surgeon-led demand patterns and demographic aging would sustain premium valuations for companies with clinical differentiation. McCormick's early recognition that orthopedics lacked a dedicated private equity consolidator shaped the firm's founding thesis, and that single-sector focus has remained intact for over two decades. HealthPointCapital targets control buyouts and significant minority growth investments in medical device companies generating between $10 million and $100 million in revenue. The portfolio spans spinal implant developers, extremity reconstruction specialists, dental implant manufacturers, and enabling digital-health tools for surgical planning. The firm deploys capital through a standard 10-year closed-end fund structure that emphasizes hands-on operational value creation over financial engineering. Its surgeon advisory network — a group of practicing clinicians — participates in deal evaluation and post-acquisition product development, giving the firm a sourcing edge in identifying which technologies will gain KOL (key opinion leader) adoption inside teaching hospitals. The geographic footprint centers on North America and Western Europe, where regulatory pathways for Class II and Class III devices remain the most predictable and the ASC (ambulatory surgery center) migration is furthest along. Team size and total capital deployed remain publicly undisclosed; HealthPointCapital does not publish fund closes or management-fee structures. The firm's low public profile is consistent with a strategy that prioritizes surgeon relationships over investor-relations marketing. Adjacent vehicles — a philanthropic foundation or co-investment sidecar — have not been publicly documented, though the firm has historically offered LP co-investment rights on a deal-by-deal basis. The leadership group includes Partners Morten Bertelsen and David Donohue, who work alongside McCormick on sourcing and portfolio management. HealthPointCapital's structural differentiator is its clinical advisory board model, which embeds practicing orthopedic and dental surgeons directly into the investment process — a governance feature that functions like a permanent, unpaid strategic consultancy and partially insulates the firm from the commoditized auction processes that dominate generalist healthcare private equity. This sourcing architecture makes scale difficult to build quickly but produces proprietary-deal volume that competitors without clinical networks struggle to match in the same sub-sectors.
General information
Firm type
Private Equity
Year founded
2002
AUM
$500M - $1.5B (Altss estimate)
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
John C. McCormick
Founder & Managing Partner
Morten Bertelsen
Partner
David T. Donohue
Partner
Sector focus
Frequently asked questions
What is HealthPointCapital's investment thesis?
HealthPointCapital concentrates exclusively on the musculoskeletal sector — orthopedics, spine, and dental technology. The firm argues that demographic-driven procedure volume growth, surgeon preference for clinically differentiated implants, and fragmentation among mid-sized device manufacturers create an opportunity to build market-leading platforms that generalist healthcare funds overlook. Its centralized thesis means every investment fits the same clinical and regulatory expertise the team has developed over two decades.
How does the clinical advisory board influence investment decisions?
The firm maintains a network of practicing orthopedic and dental surgeons who evaluate the clinical validity of every potential acquisition target. These surgeons assess whether a device's biomechanical claims are credible, whether the regulatory pathway is realistic, and whether practicing clinicians will actually adopt the technology. This clinical vetting layer reduces the risk that HealthPointCapital acquires a technically weak product that marketing alone cannot save.
Does HealthPointCapital invest outside of medical devices?
HealthPointCapital has historically confined its investments to musculoskeletal medical devices — implants, instruments, biologics, and enabling surgical technologies within orthopedics, spine, and dental. The firm does not invest in pharmaceuticals, biotech platforms, healthcare services, or provider roll-ups, even within the same anatomical specialties. This narrow mandate is a deliberate choice to preserve depth of clinical sourcing and operational expertise.
What is HealthPointCapital's typical deal size range?
The firm targets control equity investments in companies with $10 million to $100 million in revenue, a range that captures the middle-market musculoskeletal manufacturers most likely to benefit from institutional operational support. Larger strategic acquirers — Stryker, Zimmer Biomet, Dentsply Sirona — typically bid for assets above this band, leaving HealthPointCapital a less competitive auction environment for platform-sized acquisitions.
Is HealthPointCapital raising a fund currently?
HealthPointCapital does not publicly disclose fund timelines, closes, or target sizes. The firm maintains a low public-marketing posture and raises capital on a relationship-driven basis from endowments, foundations, and family offices with long-duration healthcare allocations. Public filings would appear in SEC Form D notices, but the firm's last confirmed fund close has not been reported by institutional-tracker publications.
How is HealthPointCapital differentiated from other healthcare private equity firms?
Most healthcare PE firms operate across multiple sub-sectors — services, pharma services, devices, payor-tech — with broad mandates intended to increase deal volume. HealthPointCapital is a pure-play musculoskeletal investor. That concentration creates sourcing advantages through surgeon relationships and clinical-advisory board referrals, but it also means the firm cannot pivot into hot sub-sectors when device multiples compress. Allocators weigh that sector-risk concentration against the sourcing edge.
Where are HealthPointCapital's portfolio companies primarily located?
Portfolio companies are concentrated in North America and Western Europe, where the orthopedic and dental device regulatory frameworks are mature, surgeon reimbursement is well-understood, and the ASC (ambulatory surgery center) site-of-care migration is most advanced. The firm has not disclosed a material emerging-markets exposure, which aligns with the regulatory complexity of Class II and Class III implant approvals outside established jurisdictions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: